High Rates of Drug-induced Liver Injury in People Living With HIV Coinfected With Tuberculosis (TB) Irrespective of Antiretroviral Therapy Timing During Antituberculosis Treatment: Results From the Starting Antiretroviral Therapy at Three Points in TB Trial

Abstract Background New onset or worsening drug-induced liver injury challenges coinfected patients on antiretroviral therapy (ART) initiation during antituberculosis (TB) treatment. Methods Post hoc analysis within a randomized trial, the Starting Antiretroviral Therapy at Three Points in Tuberculo...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2020-06, Vol.70 (12), p.2675-2682
Main Authors: Naidoo, Kogieleum, Hassan-Moosa, Razia, Mlotshwa, Philile, Yende-Zuma, Nonhlanhla, Govender, Dhineshree, Padayatchi, Nesri, Abdool-Karim, Salim S S
Format: Article
Language:English
Subjects:
Adult
Aged
and Commentaries
Anti-HIV Agents - therapeutic use
CD4 Lymphocyte Count
Chemical and Drug Induced Liver Injury - epidemiology
Chemical and Drug Induced Liver Injury - etiology
Coinfection - drug therapy
HIV Infections - complications
HIV Infections - drug therapy
Humans
Tuberculosis - complications
Tuberculosis - drug therapy
Tuberculosis - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background New onset or worsening drug-induced liver injury challenges coinfected patients on antiretroviral therapy (ART) initiation during antituberculosis (TB) treatment. Methods Post hoc analysis within a randomized trial, the Starting Antiretroviral Therapy at Three Points in Tuberculosis trial, was conducted. Patients were randomized to initiate ART either early or late during TB treatment or after TB treatment completion. Liver enzymes were measured at baseline, 6-month intervals, and when clinically indicated. Results Among 642 patients enrolled, the median age was 34 years (standard deviation, 28–40), and 17.6% had baseline CD4+ cell counts
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciz732